Levodopa-Induced Dyskinesia in Parkinson's Disease

This book aims to provide a single reference source on levodopa-induced dyskinesias (LID) from ‘bench to bedside’.

Initial chapters review the clinical features and phenomenology of LID with video examples; epidemiology and genetic risk factors for LID are covered as a background to understanding risk factors for developing LID. The following chapters cover the latest preclinical studies aiming to understand the pathophysiology of LID at the cellular, neurochemical, neurophysiological and circuitry level with detailed discussion of mechanisms and future directions to take the field forward; clinical studies from phase II to phase IV; on going RCTs in LID and evidence-based medicine reviews of treatment options.

Levodopa-Induced Dyskinesia in Parkinson’s Disease is aimed at an international audience of movement disorder neurologists; neuroscientists; trainees and graduate and post-graduate students.

• Parkinson's disease
• clinical trial
• dyskinesia
• levodopa
• levodopa-induced dyskinesia
• parkinsonism
• preclinical study

• Toronto Western Hospital, Toronto, Canada

  Susan H. Fox, Jonathan M. Brotchie

Dr Susan Fox is Associate Professor of Neurology at Toronto Western Hospital, University Health Network and University of Toronto, Canada. She has many years’ experience in preclinical models of Parkinson's disease and translational studies of novel pharmacological therapies for Parkinson’s disease and dyskinesia. She has expertise in the design and running of phase II and III clinical studies in movement disorders. She has received funding from NIH, CIHR, Parkinson Society Canada and Michael J Fox Foundation for research into PD. She has published over 120 peer reviewed papers, reviews and book chapters in the field and is a regular speaker at national and international conferences. Dr Fox is an active member of the International Parkinson and Movement Disorder Society (MDS). She is current co-editor of the MDS website and chair of the MDS evidence based medicine committee on reviews of treatments for movement disorders.

Jonathan Brotchie, PhD, is Senior Scientist at the Toronto Western Hospital, University Health Network (UHN). At UHN, he leads a research programme focused on the discovery and validation of novel therapeutic targets for Parkinson’s disease and the development of therapeutics based upon those targets. The particular expertise of his group and collaborators at UHN lies in transitioning development programmes from pre-clinical efficacy to Phase II proof-of-concept. Dr Brotchie is also Founder and a Director of Atuka Ltd, a CRO specialising in the provision of support for developing therapies for neurodegenerative disorders.

Policies and ethics